Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Lymphoma 25Small Cell Lung Carcinoma 23Leukemia 18Lymphoma, Large B-Cell, Diffuse 17Lung Neoplasms 15Precursor Cell Lymphoblastic Leukemia-Lymphoma 14Lymphoma, Non-Hodgkin 14Lymphoma, Extranodal NK-T-Cell 11Hodgkin Disease 10Leukemia, Myeloid, Acute 8Carcinoma, Non-Small-Cell Lung 8Ovarian Neoplasms 7Neuroblastoma 7Lymphoma, Mantle-Cell 7Burkitt Lymphoma 7Recurrence 6Lymphoma, T-Cell, Peripheral 6Central Nervous System Neoplasms 6Retinoblastoma 5Lymphoma, Large-Cell, Immunoblastic 5Lymphohistiocytosis, Hemophagocytic 5Breast Neoplasms 5Testicular Neoplasms 4Multiple Myeloma 4Lymphoma, Follicular 4Leukemia, Myelomonocytic, Acute 4Leukemia, Monocytic, Acute 4Leukemia, Megakaryoblastic, Acute 4Leukemia, Erythroblastic, Acute 4Teratoma 3

Interventions

anlotinib 1Etoposide 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Unknown × SCLC × Etoposide × Clear all
NCT04684017 2020-12-24

Anlotinib Plus Etoposide and Carboplatin as First-line Treatment for Extensive-stage Small Cell Lung Cancer

Shanghai Chest Hospital

Phase 2 Unknown
29 enrolled
Thoracic

SCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡